While c‐Myc‐i7 (IC50 of 83.7 μM) demonstrated efficacy similar to that of 10058‐F4, c‐Myc‐i8 displayed reduced efficacy in lung cancer (IC50 of 145.5 μM). This evidence concerns the gene MYC and lung carcinoma.